特變電工(600089.SH):科技投資公司向首鋼智新增資3億元
格隆匯12月19日丨特變電工(600089.SH)公佈,為進一步增強資金實力,貫徹落實國家關於國有企業混合所有制改革相關政策,首鋼智新在北京產權交易所掛牌了《首鋼智新遷安電磁材料有限公司增資項目》,通過增資擴股的方式引入戰略投資者。公司全資子公司特變電工科技投資有限公司(簡稱科技投資公司)通過競標及競爭性談判成為其戰略投資者。
2022年12月19日科技投資公司與首鋼智新、首鋼股份等股東簽署了《關於首鋼智新遷安電磁材料有限公司之增資協議》,科技投資公司以貨幣資金3億元向首鋼智新增資,佔其增資後註冊資本的1.4661%。此次科技投資公司向首鋼智新增資的資金以科技投資公司自有資金解決。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.